FDA accepts ELIQUIS® (apixaban) New Drug Application for review
29 November 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. FDA has accepted for review a NDA for ELIQUIS® (apixaban)...
List view / Grid view
29 November 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. FDA has accepted for review a NDA for ELIQUIS® (apixaban)...
22 November 2011 | By Pfizer
Lead program includes novel investigational compound for prevention/treatment of skin scarring...
21 November 2011 | By Pfizer
10-year lease marks a strategic partnership between the academic research community and industry to boost innovation...
21 November 2011 | By Pfizer
Pfizer Inc. announced that its Market Authorisation Application for tofacitinib...
13 November 2011 | By Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announced the results of the Phase 3 ADOPT trial...
7 November 2011 | By Pfizer
Investigator research on several pfizer compounds to be presented...
5 November 2011 | By Pfizer
PRESERVE trial results...
1 November 2011 | By College Hill
Sanofi is expected to take the top spot amongst the world’s pharmaceuticals manufacturers in 2012...
28 October 2011 | By Pfizer
Pfizer Inc. has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen...
13 October 2011 | By Pfizer
New research collaboration will leverage data & experience to improve seniors’ well-being...
3 October 2011 | By Ogilvy Healthworld UK Limited
Pfizer announce the launch of BeneFIX® with Room Temperature Storage (RTS)....
13 September 2011 | By Pfizer
Eclipse, extended the expiration date of the subsequent offering period of its tender offer...
6 September 2011 | By Pfizer
Pfizer and Icagen announced the successful completion of the initial cash tender offer...
5 September 2011 | By Pfizer
Expiration date of its tender offer for all outstanding shares of common stock of Icagen has been extended...
2 September 2011 | By Pfizer
Facility to house cardiovascular, metabolic and endocrine disease and neuroscience research units...